ArticleGels (Basel, Switzerland)2022
Increasing the Hydrophobic Component of Poloxamers and the Inclusion of Salt Extend the Release of Bupivacaine from Injectable In Situ Gels, While Common Polymer Additives Have Little Effect.
Article in Gels (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Dissolving Microneedles with Smart Design-A Tool for Enhancing Skin Permeation of Naltrexone Hydrochloride.Molecules (Basel, Switzerland) · 2026Article
- Erratum: effect of poloxamer and hyaluronic acid administration in nerve root fibrosis and adhesion prevention following laminectomy: a novel bibliometric analysis.Orthopedic reviews · 2026Article
- effect of poloxamer and hyaluronic acid administration in nerve root fibrosis and adhesion prevention following laminectomy: a novel bibliometric analysis.Orthopedic reviews · 2026Article
- Tuning Pluronic Hydrogel Properties via Ionic Strength and Hyaluronic Acid for Optimized Rheology and Drug Delivery Performances.ACS omega · 2025Article
- Investigation of Rheological Characteristics of Thermosensitive Nasal In Situ Gels Based on P407 and Their Effect on Spray Pattern.Gels (Basel, Switzerland) · 2025Article
- In Situ Forming Poloxamer-Based Thermo-Sensitive Hydrogels for Ocular Application: A Focus on the Derivatives 407 and 188.Gels (Basel, Switzerland) · 2025Review
- Article
- Thermosensitive Mucoadhesive Intranasal In Situ Gel of Risperidone for Nose-to-Brain Targeting: Physiochemical and Pharmacokinetics Study.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Poloxamer-based thermosensitive injectable hydrogels containing a self-assembling peptide forComputational and structural biotechnology journal · 2025Article
- Rheological and Injectability Evaluation of Sterilized Poloxamer-407-Based Hydrogels Containing Docetaxel-Loaded Lipid Nanoparticles.Gels (Basel, Switzerland) · 2024Article
- Development of Carvedilol Nanoformulation-Loaded Poloxamer-Based In Situ Gel for the Management of Glaucoma.Gels (Basel, Switzerland) · 2023Article
- Design and Evaluation of Paeonol-Loaded Liposomes in Thermoreversible Gels for Atopic Dermatitis.Gels (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Various strategies have been applied to reduce the initial burst of drug release and sustain release from poloxamer-based thermoresponsive gels. This work focussed on investigating different formulation approaches to minimise the initial burst of release and sustain the release of the small hydrophilic drug bupivacaine hydrochloride from poloxamer-based thermoresponsive gels. Various in situ gel formulations were prepared by varying the polypropylene oxide (PPO)/polyethylene oxide (PEO) ratio and by adding additives previously described in the literature. It was observed that increasing the PPO/PEO ratio from 0.28 to 0.30 reduced the initial burst release from 17.3% ± 1.8 to 9.1% ± 1.2 during the first six hours and extended the release profile from 10 to 14 days. Notably, the inclusion of sodium chloride (NaCl 0.4%
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.